Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma

Michal Alon¹, Rand Arafeh¹, Joo Sang Lee^{2

3}, Sanna Madan^{2

3}, Shelly Kalaora¹, Adi Nagler¹, Tereza Abgarian¹, Polina Greenberg¹, Eytan Ruppin^{2

3}, Yardena Samuels¹

Affiliations

¹ Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, Israel.
² Center for Bioinformatics and Computational Biology, The University of Maryland, College Park, Maryland, USA.
³ Cancer Data Science Lab, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.

Published Erratum

Michal Alon et al. Oncotarget. 2019.

. 2019 Feb 12;10(13):1344.

doi: 10.18632/oncotarget.26685.

Michal Alon¹, Rand Arafeh¹, Joo Sang Lee^{2

3}, Sanna Madan^{2

3}, Shelly Kalaora¹, Adi Nagler¹, Tereza Abgarian¹, Polina Greenberg¹, Eytan Ruppin^{2

3}, Yardena Samuels¹

¹ Molecular Cell Biology Department, Weizmann Institute of Science, Rehovot, Israel.
² Center for Bioinformatics and Computational Biology, The University of Maryland, College Park, Maryland, USA.
³ Cancer Data Science Lab, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.25805.].

CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.
Alon M, Arafeh R, Lee JS, Madan S, Kalaora S, Nagler A, Abgarian T, Greenberg P, Ruppin E, Samuels Y. Alon M, et al. Oncotarget. 2018 Jul 27;9(58):31264-31277. doi: 10.18632/oncotarget.25805. eCollection 2018 Jul 27. Oncotarget. 2018. PMID: 30131853 Free PMC article.